Abstract
The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Keywords: HLA class I, cancer, immune escape
Current Cancer Therapy Reviews
Title: HLA Class I Expression, Tumor Escape and Cancer Progression
Volume: 4 Issue: 2
Author(s): Natalia Aptsiauri, Teresa Cabrera, Angel Garcia Lora, Francisco Ruiz-Cabello and Federico Garrido
Affiliation:
Keywords: HLA class I, cancer, immune escape
Abstract: The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Export Options
About this article
Cite this article as:
Aptsiauri Natalia, Cabrera Teresa, Lora Garcia Angel, Ruiz-Cabello Francisco and Garrido Federico, HLA Class I Expression, Tumor Escape and Cancer Progression, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310052
DOI https://dx.doi.org/10.2174/157339408784310052 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Editorial [Hot Topic: Anticancer Macromolecular Prodrugs in Clinical Trials - an Update (Guest Editor: Felix Kratz)]
Current Bioactive Compounds Magnetic Materials for the Selective Analysis of Peptide and Protein Biomarkers
Current Medicinal Chemistry Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor
Recent Patents on Anti-Cancer Drug Discovery Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat
Drug Metabolism Letters A Review of Molecular Predictors of Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Mini-Reviews in Medicinal Chemistry Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Current Drug Delivery Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry
Current Medicinal Chemistry Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Recent Development in Identification of Potential Novel Therapeutic Targets Against Trypanosomatids
Current Topics in Medicinal Chemistry Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry